+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Characterization and inhibition of SARS-coronavirus main protease



Characterization and inhibition of SARS-coronavirus main protease



Current Topics in Medicinal Chemistry 6(4): 361-376



Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by a novel human coronavirus (CoV). During the 2003 epidemic, the disease rapidly spread from its origin in southern China to other countries and affected almost 8000 patients, which resulted in about 800 fatalities. A chymotrypsin-like cysteine protease named 3C-like protease (3CLpro) is essential for the life cycle of the SARS-CoV. This main protease is responsible for maturation of functional proteins and represents a key anti-viral target. HPLC and fluorescence-based assays have been used to characterize the protease and to determine the potency of the inhibitors. The fluorogenic method monitoring the increase of fluorescence from the cleavage of a peptide substrate containing an Edans-Dabcyl fluorescence quenching pair at two ends has enabled the use of high throughput screening to speed up the drug discovery process. Several groups of inhibitors have been identified through high throughput screening and rational drug design approaches. Thus, alpha,beta-unsaturated peptidomimetics, anilides, metal-conjugated compounds, boronic acids, quinolinecarboxylate derivatives, thiophenecarboxylates, phthalhydrazide-substituted ketoglutamine analogues, isatin and natural products have been identified as potent inhibitors of the SARS-CoV main protease. The different classes of inhibitors reported in these studies are summarized in this review. Some of these inhibitors could be developed into potential drug candidates, which may provide a solution to combat possible reoccurrence of the SARS and other life-threatening viruses with 3CL proteases.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048495943

Download citation: RISBibTeXText

PMID: 16611148


Related references

Characterization and Inhibition of Sars-Coronavirus Main Protease. Current Topics in Medicinal Chemistry 6(4): 361-376, 2006

An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors. Chembiochem 7(7): 1048-1055, 2006

Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. Biochemistry 44(30): 10349-10359, 2005

Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs. Febs Letters 574(1-3): 131-137, 2004

Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43(17): 4906-4912, 2004

Inhibitor Design for Sars Coronavirus Main Protease Based on Distorted Key Theory. Medicinal Chemistry 3(1): 1-6, 2007

Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease. Biophysical Journal 98(7): 1327-1336, 2010

Inhibitor design for SARS coronavirus main protease based on "distorted key theory". Medicinal Chemistry ) 3(1): 1-6, 2007

Mechanism for controlling the monomer-dimer conversion of SARS coronavirus main protease. Acta Crystallographica. Section D Biological Crystallography 69(Pt 5): 747-755, 2013

Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry 43(47): 14958-14970, 2004

Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease. Antiviral Research 92(2): 204-212, 2011

Substrate specificity and rational design of peptidomimetic inhibitors for SARS coronavirus main protease. Hong Kong Medical Journal 20(Suppl. 4): 18-21, 2014

Dynamic ligation screening: The site-directed discovery of low affinity inhibitory fragments binding to SARS coronavirus main protease. 2007

Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnology Letters 34(5): 831-838, 2012

Evaluation of homology modeling of the severe acute respiratory syndrome (SARS) coronavirus main protease for structure based drug design. Chemical & Pharmaceutical Bulletin 52(5): 643-645, 2004